Published May 4, 2021, 2:51 PM
The Food and Drug Administration (FDA) on Tuesday, May 4, said it cannot assure for the safety and quality of the products used under the condition of a Compassionate Special Permit (CSP) as it did not undergo evaluation by the agency.
Food and Drug Administration (FDA) Director General Eric Domingo
FDA Director General Eric Domingo said an unregistered drug, medical device, or food product used under the condition of a CSP does not undergo evaluation by the FDA.
“So when we give a compassionate special permit it is very clear that we have no assurance of safety, efficacy, and quality because it did not undergo evaluation with the FDA,” Domingo said in virtual press briefing.